Cabozantinib Capsules and Phenobarbital Sodium
Determining the interaction of Cabozantinib Capsules and Phenobarbital Sodium and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:PHENobarbital may significantly reduce the blood levels of cabozantinib, which may make the medication less effective in treating your cancer. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme. In healthy subjects, administration of the potent CYP450 3A4 inducer rifampin (600 mg daily for 31 days) decreased single-dose cabozantinib plasma exposure (AUC) by 77%. Reduced therapeutic efficacy of cabozantinib may occur.
MANAGEMENT: Chronic use of potent CYP450 3A4 inducers during treatment with cabozantinib should be avoided whenever possible. If chronic coadministration is required, the daily dosage of cabozantinib should be increased in accordance with the prescribing information for the specific product. For the treatment of progressive, metastatic medullary thyroid cancer (capsule formulation), the recommendation is to increase cabozantinib dosage by 40 mg (e.g., from 140 mg to 180 mg daily or from 100 mg to 140 mg daily) as tolerated, not to exceed 180 mg/day. For the treatment of advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy (tablet formulation), the recommendation is to increase cabozantinib dosage by 20 mg (e.g., from 60 mg to 80 mg daily or from 40 mg to 60 mg daily) as tolerated, not to exceed 80 mg/day. The original dosage of cabozantinib may be resumed 2 to 3 days after discontinuation of the potent CYP450 3A4 inducer.
- "Product Information. Cabometyx (cabozantinib)." Exelixis Inc, S San Francisco, CA.
- "Product Information. Cometriq (cabozantinib)." Exelixis Inc, S San Francisco, CA.
Generic Name: cabozantinib
Brand name: Cabometyx, Cometriq
Synonyms: Cabozantinib
Generic Name: phenobarbital
Brand name: Solfoton, Luminal
Synonyms: Phenobarbital, PHENobarbital
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cabozantinib Capsules-Phenobarbital Sodium Injection
- Cabozantinib Capsules-Phenobarbital Tablets
- Cabozantinib Capsules-Phenobarbital with Belladonna Alkaloids Elixir
- Cabozantinib Capsules-Phenohytro
- Cabozantinib Capsules-Phenohytro Elixir
- Cabozantinib Capsules-Phenoxybenzamine
- Phenobarbital Sodium-Cabozantinib S-malate
- Phenobarbital Sodium-Cabozantinib Tablets
- Phenobarbital Sodium-Caduet
- Phenobarbital Sodium-Cafcit
- Phenobarbital Sodium-Cafcit (Caffeine Citrate Injection Solution)
- Phenobarbital Sodium-Cafcit (Caffeine Citrate Oral Solution)